𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗔𝗜-𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗚𝗟𝗣-𝟭 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝘄𝗶𝘁𝗵 𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗖𝗹𝗮𝘀𝘀 𝗗𝘂𝗮𝗹-𝗣𝗮𝘁𝗵𝘄𝗮𝘆 𝗥𝗲𝗴𝗶𝗺𝗲𝗻 𝗳𝗼𝗿 𝗔𝗴𝗶𝗻𝗴 𝗮𝗻𝗱 𝗟𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 A major advancement in MindWalk’s GLP-1 therapeutics program reveals a

𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Earlier today, we announced our transition to MindWalk™ (NASDAQ: HYFT). The vision is now reality: one brand uniting technology, data and science to reshape discovery.

Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”. Today, IPA (ImmunoPrecise Antibodies), along with BioStrand and Talem, unify under a single identity: MindWalk. This evolution marks more than a name change. It reflects a strategic

𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗜𝗺𝗺𝘂𝗻𝗼𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗵𝗮𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝘁𝗵𝗲 𝘀𝗮𝗹𝗲 𝗼𝗳 𝗶𝘁𝘀 𝗡𝗲𝘁𝗵𝗲𝗿𝗹𝗮𝗻𝗱𝘀 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝘁𝗼 𝗔𝗩𝗦 𝗕𝗶𝗼 𝗶𝗻 𝗮 𝘁𝗿𝗮𝗻𝘀𝗮𝗰𝘁𝗶𝗼𝗻 𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝘁 $𝟭𝟮 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗨𝗦𝗗. A focused move that strengthens

Press Release: IPA advances universal Dengue Vaccine Initiative: moves into preclinical antibody generation Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSᵃⁱ™ platform powered by patented HYFT®

MindWalk $HYFT – A Bold New Era in Bio-Native AI Discovery ImmunoPrecise $IPA has officially rebranded as MindWalk and will now trade under the new ticker $HYFT. This transformation unifies its subsidiaries into one powerhouse brand and signals a shift from traditional wet-lab

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽.™ (𝗳𝗼𝗿𝗺𝗲𝗿𝗹𝘆 𝗜𝗺𝗺𝘂𝗻𝗼𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀™ 𝗟𝗧𝗗): 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗥𝗲𝗰𝗼𝗿𝗱 $𝟳.𝟲 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗤𝘂𝗮𝗿𝘁𝗲𝗿𝗹𝘆 𝗥𝗲𝘃𝗲𝗻𝘂𝗲, 𝟰𝟱% 𝗚𝗿𝗼𝘄𝘁𝗵, 𝗠𝗮𝗿𝗴𝗶𝗻 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻, 𝗡𝗮𝗿𝗿𝗼𝘄𝗲𝗱

Press Release: ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York. Dr. Jennifer Bath, President and CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the

𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿: 𝗙𝗬𝟮𝟲 𝗤𝟭 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗰𝗮𝗹𝗹 Join us Monday, September 15, 2025, at 10:30am EST for an update on quarterly highlights fueling growth. **𝗜𝗣𝗔 𝗮𝗻𝗱 𝗶𝘁𝘀 𝘀𝘂𝗯𝘀𝗶𝗱𝗶𝗮𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝗻𝗼𝘄 𝘂𝗻𝗶𝗳𝗶𝗲𝗱 𝘂𝗻𝗱𝗲𝗿 𝗼𝗻𝗲

$IPA ImmunoPrecise Antibodies Ltd. for some reason really like this symbol...

AI-Driven Biotech Stock Poised for 600% Surge with Record Growth and Game-Changing Innovations! 🚨 $IPA ImmunoPrecise Antibodies🚨 🔸The LENSai platform and HYFT technology accelerate antibody discovery, outpacing competitors with breakthroughs like GLP-1 peptides surpassing

𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗜𝗣𝗔 𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝘀 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗱𝗮𝘁𝗮 𝘃𝗶𝘀𝗶𝗼𝗻𝗮𝗿𝘆 𝗝𝗲𝗳𝗳 𝗙𝗿𝗶𝗲𝗱, 𝗜𝗻𝘁𝗲𝗿𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁, 𝘁𝗼 𝗮𝗱𝘃𝗶𝘀𝗼𝗿𝘆 𝗯𝗼𝗮𝗿𝗱 Jeff Fried, a recognized leader in

#BigRigAlert 🚨 $HYFT @ImmunoPrecise @BioStrandBV Six month trend is my friend! $XBI and $HYFT both looking primed for another big run here. Boat loaded and looking forward to multiple news releases before the end of year. #BrightFuture 📈📈📈

$IPA Immunoprecise (IPA.O) Surges 32%—What’s Behind the Sharp Move? - AInvest #stocks #news

Take a look at @ImmunoPrecise - very cool use of AI!!! 👀👀👀 $HYFT https://t.co/83XBAMyNvd

$HYFT ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT" - Yahoo Finance #stocks #news

$IPA AI stock with more than 400% upside potential!! Latest News - According to Benzinga, "Immunoprecise Antibodies Announces Results Of A Newly Expanded Study Demonstrating That Its Lensai Immunogenicity Screening Can Reliably Predict Anti-Drug-Antibody Risk For Therapeutic

𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: New study demonstrates LENSᵃⁱ™ can reliably predict ADA risk, supporting earlier and broader immunogenicity screening Anti-Drug Antibody (ADA) responses remain one of the most costly late-stage risks in biologics development—delaying launches by

𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗤𝟰 𝗮𝗻𝗱 𝗳𝗶𝘀𝗰𝗮𝗹 𝘆𝗲𝗮𝗿 𝗲𝗻𝗱 𝟮𝟬𝟮𝟱 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗹𝗹. Join us July 29, 2025, at 10:30am EST for an update on quarterly key highlights fueling market growth.